637 related articles for article (PubMed ID: 33938493)
1. A Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Therapy With or Without Panitumumab After Hepatic Resection of KRAS Wild-type Colorectal Cancer.
Kemeny NE; Chou JF; Capanu M; Chatila WK; Shi H; Sanchez-Vega F; Kingham TP; Connell LC; Jarnagin WR; D'Angelica MI
Ann Surg; 2021 Aug; 274(2):248-254. PubMed ID: 33938493
[TBL] [Abstract][Full Text] [Related]
2. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
Carrato A; Abad A; Massuti B; Grávalos C; Escudero P; Longo-Muñoz F; Manzano JL; Gómez A; Safont MJ; Gallego J; García-Paredes B; Pericay C; Dueñas R; Rivera F; Losa F; Valladares-Ayerbes M; González E; Aranda E;
Eur J Cancer; 2017 Aug; 81():191-202. PubMed ID: 28633089
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer.
Kemeny N; Jarnagin W; Gonen M; Stockman J; Blumgart L; Sperber D; Hummer A; Fong Y
J Clin Oncol; 2003 Sep; 21(17):3303-9. PubMed ID: 12947066
[TBL] [Abstract][Full Text] [Related]
4. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in
Modest DP; Karthaus M; Fruehauf S; Graeven U; Müller L; König AO; Fischer von Weikersthal L; Caca K; Kretzschmar A; Goekkurt E; Haas S; Kurreck A; Stahler A; Held S; Jarosch A; Horst D; Reinacher-Schick A; Kasper S; Heinemann V; Stintzing S; Trarbach T
J Clin Oncol; 2022 Jan; 40(1):72-82. PubMed ID: 34533973
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
6. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
Fornaro L; Lonardi S; Masi G; Loupakis F; Bergamo F; Salvatore L; Cremolini C; Schirripa M; Vivaldi C; Aprile G; Zaniboni A; Bracarda S; Fontanini G; Sensi E; Lupi C; Morvillo M; Zagonel V; Falcone A
Ann Oncol; 2013 Aug; 24(8):2062-7. PubMed ID: 23666916
[TBL] [Abstract][Full Text] [Related]
7. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer.
House MG; Kemeny NE; Gönen M; Fong Y; Allen PJ; Paty PB; DeMatteo RP; Blumgart LH; Jarnagin WR; D'Angelica MI
Ann Surg; 2011 Dec; 254(6):851-6. PubMed ID: 21975318
[TBL] [Abstract][Full Text] [Related]
8. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer.
Kemeny N; Capanu M; D'Angelica M; Jarnagin W; Haviland D; Dematteo R; Fong Y
Ann Oncol; 2009 Jul; 20(7):1236-41. PubMed ID: 19233901
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases.
Kemeny N; Conti JA; Sigurdson E; Cohen A; Seiter K; Lincer R; Niedzwiecki D; Botet J; Chapman D; Costa P
Cancer; 1993 Mar; 71(6):1964-71. PubMed ID: 8443746
[TBL] [Abstract][Full Text] [Related]
11. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Peeters M; Oliner KS; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; He P; Yu H; Koukakis R; Terwey JH; Jung AS; Sidhu R; Patterson SD
Clin Cancer Res; 2015 Dec; 21(24):5469-79. PubMed ID: 26341920
[TBL] [Abstract][Full Text] [Related]
12. Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52.
Bolton JS; O'Connell MJ; Mahoney MR; Farr GH; Fitch TR; Maples WJ; Nagorney DM; Rubin J; Fuloria J; Steen PD; Alberts SR
Clin Colorectal Cancer; 2012 Mar; 11(1):31-7. PubMed ID: 21729678
[TBL] [Abstract][Full Text] [Related]
13. Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.
Shitara K; Yonesaka K; Denda T; Yamazaki K; Moriwaki T; Tsuda M; Takano T; Okuda H; Nishina T; Sakai K; Nishio K; Tokunaga S; Yamanaka T; Boku N; Hyodo I; Muro K
Cancer Sci; 2016 Dec; 107(12):1843-1850. PubMed ID: 27712015
[TBL] [Abstract][Full Text] [Related]
14. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
Seymour MT; Brown SR; Middleton G; Maughan T; Richman S; Gwyther S; Lowe C; Seligmann JF; Wadsley J; Maisey N; Chau I; Hill M; Dawson L; Falk S; O'Callaghan A; Benstead K; Chambers P; Oliver A; Marshall H; Napp V; Quirke P
Lancet Oncol; 2013 Jul; 14(8):749-59. PubMed ID: 23725851
[TBL] [Abstract][Full Text] [Related]
15. Extrahepatic recurrence rates in patients receiving adjuvant hepatic artery infusion and systemic chemotherapy after complete resection of colorectal liver metastases.
Srouji RM; Narayan RR; Boerner T; Buisman FE; Seier K; Gonen M; Balachandran VP; Drebin JA; Jarnagin WR; Kingham TP; Wei A; Kemeny NE; D'Angelica MI
J Surg Oncol; 2020 Dec; 122(8):1536-1542. PubMed ID: 32976666
[TBL] [Abstract][Full Text] [Related]
16. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
[TBL] [Abstract][Full Text] [Related]
17. Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy.
Kemeny NE; Chou JF; Boucher TM; Capanu M; DeMatteo RP; Jarnagin WR; Allen PJ; Fong YC; Cercek A; D'Angelica MI
J Surg Oncol; 2016 Apr; 113(5):477-84. PubMed ID: 26830685
[TBL] [Abstract][Full Text] [Related]
18. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR
Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038
[TBL] [Abstract][Full Text] [Related]
19. A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only.
Bendell JC; Zakari A; Peyton JD; Boccia R; Moskowitz M; Gian V; Lipman A; Waterhouse D; LoCicero R; Earwood C; Lane CM; Meluch A
Oncologist; 2016 Mar; 21(3):279-80. PubMed ID: 26911408
[TBL] [Abstract][Full Text] [Related]
20. Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C.
Link KH; Kornmann M; Leder G; Pillasch AF; Sunelaitis E; Schatz M; Pressmar J; Beger HG
Gan To Kagaku Ryoho; 1999 Feb; 26(3):269-81. PubMed ID: 10065089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
